Download Advances in pulmonary drug delivery by Philip Chi Lip Kwok, Hak-Kim Chan PDF

By Philip Chi Lip Kwok, Hak-Kim Chan

The breathing tract has been used to convey biologically energetic chemical compounds into the human physique for hundreds of years. even though, the lungs are complicated of their anatomy and body structure, which poses demanding situations to drug supply. Inhaled formulations are mostly extra refined than these for oral and parenteral management. Pulmonary drug improvement is for this reason a hugely really expert region as a result of its many special concerns and demanding situations. fast growth is being made and provides novel options to current remedy difficulties. Advances in Pulmonary Drug Delivery highlights the newest advancements during this field.

Show description

Read or Download Advances in pulmonary drug delivery PDF

Best pulmonary & thoracic medicine books

Intensive Care Medicine in 10 Years

Even supposing its roots date again to the early many years of the 20 th century, serious care medication didn't grow to be a area of expertise in drugs until eventually the 1970’s. over the past 30 years or so, the sector of serious care drugs has grown vastly and there's now an exceptional physique of clinical details that kinds the root for the perform of severe care drugs.

Pulmonary Manifestations of Rheumatic Disease, An Issue of Clinics in Chest Medicine (The Clinics: Internal Medicine)

This factor brilliantly pairs a rheumatologist with a pulmonologist to discover all of the 14 article topics.  themes contain autoantibody checking out, ultility of bronchoalveolar lavage in autoimmune illness, and pulmonary manifestations of such stipulations as scleroderma, rheumatoid arthritis, lupus erythematosus, Sjogren's Syndrome, Inflammatory Myopathies, and Relapsing Polychondritis.

The Thorax (Lung Biology in Health and Disease ; V. 85) Part A: Physiology

This well timed moment version of a landmark reference furnishes in-depth examinations of the newest advancements within the body structure, pathophysiology, and scientific relevance of the respiration muscular tissues and chest wall-reflecting the explosion of data that has happened because the book of the former variation.

Pulmonary Infection and Inflammation

Pulmonary illnesses are the foremost reason for human morbidity, taxing the well-being care approach as a result of illness occurrence, chronicity, and social and financial bills. This ebook concentrates at the inflammatory and immunogenic settings of pulmonary problems and similar scientific components. over the top irritation factors lung damage and types a conducive heritage for pathogenic infections, fairly in immuno-compromised hosts.

Extra info for Advances in pulmonary drug delivery

Sample text

1 Examples of siRNA-Based Therapeutics in Clinical Trials for Lung Diseases Product Name ALN-RSV01 Excellair™ Delivery Agent/ Route of Administration Naked siRNA/ intranasal Unknown/inhalation Latest Development Status Indication Sponsor RSV infection Alnylam pharmaceuticals Zabecor pharmaceuticals Asthma IIb (completed) II BARRIERS TO siRNA DELIVERY TO THE LUNG As illustrated in Figure 3�1, there are generally five steps that siRNA go through when administered via pulmonary route� Although local delivery of siRNA could obviate the need for targeting and the interaction with serum nuclease to minimize degradation, the lung itself possesses some intrinsic anatomic, physiologic, immunologic, and metabolic hurdles for efficient siRNA delivery� The specific barriers to lung 1.

1 Examples of siRNA-Based Therapeutics in Clinical Trials for Lung Diseases Product Name ALN-RSV01 Excellair™ Delivery Agent/ Route of Administration Naked siRNA/ intranasal Unknown/inhalation Latest Development Status Indication Sponsor RSV infection Alnylam pharmaceuticals Zabecor pharmaceuticals Asthma IIb (completed) II BARRIERS TO siRNA DELIVERY TO THE LUNG As illustrated in Figure 3�1, there are generally five steps that siRNA go through when administered via pulmonary route� Although local delivery of siRNA could obviate the need for targeting and the interaction with serum nuclease to minimize degradation, the lung itself possesses some intrinsic anatomic, physiologic, immunologic, and metabolic hurdles for efficient siRNA delivery� The specific barriers to lung 1.

ID=244� Kamada meets primary endpoint of U�S� Phase 2 study of inhaled alpha-1 antitrypsin for the treatment of alpha-1 antitrypsin deficiency� www�kamada�com/events�php� Accessed Aug 30, 2016� Inhaled Proteins and Peptides 21 29� Sabin AB� Immunization against measles by aerosol� Reviews of Infectious Diseases 5: 514–523 (1983)� 30� Valdespino-Gomez JL, de Lourdes Garcia-Garcia M, Fernandez-de-Castro J, HenaoRestrepo AM, Bennett J, Sepulveda-Amor J� Measles aerosol vaccination� Current Topics in Microbiology and Immunology 304: 165–193 (2006)� 31� Henao-Restrepo AM, Greco M, Laurie X, John O, Aguado T� Measles aerosol vaccine project� Proceedia in Vaccinology 2: 147–150 (2010)� 32� WHO� Measles aerosol vaccine project: Report to SAGE (2012)� www�who�int/immunization/…/3_MeaslesAerosolVaccineProject-report� Accessed Jan, 2016� 33� Burger JL, Cape SP, Braun CS, McAdams DH, Best JA, Bhagwat P, Pathak P, Rebits LG, Sievers RE� Stabilizing formulations for inhalable powders of live-attenuated measles virus vaccine� Journal of Aerosol Medicine and Pulmonary Drug Delivery 21(1): 25–34 (2008)� 34� Lin WH, Griffin DE, Rotab PA, Papania M, Cape SP, Bennett D et al� Successful respiratory immunization with dry powder live-attenuated measles virus vaccine in rhesus macaques� Proceedings of the National Academy of Sciences of the United States of America 108(7): 2987–2992 (2011)� www�pnas�org/content/early/2011/01/26/1017334108�full�pdf� 35� Agarkhedkar S, Kulkarni SP, Winston S, Sievers R, Dhere RM, Gunale B, Powell K, Rota PA, Papania M� Safety and immunogenicity of dry powder measles vaccine administered by inhalation: A randomized controlled Phase I clinical trial� Vaccine 32: 6791–6797 (2014)� 36� Garrison Jr LP, Bauch CT, Bresnahan BW, Hazlet TK, Kadiyala S, Veenstra DL� Using cost-effectiveness analysis to support research and development portfolio prioritization for product innovations in measles vaccination� Journal of Infectious Diseases 204: S124–S132 (2011)� 37� Sweeney TD, Marian M, Achilles M, Bussiere J, Ruppel J, Shoenhoff M, Mrsny RJ� Biopharmaceutics of immunoglobin transport across lung epithelium� In Respiratory Drug Delivery VII, P Byron et al�, eds� Serentec Press, Raleigh, NC, pp� 59–66 (2000)� 38� Fahy JV, Cockcroft DW, Boulet LP, Wong HH, Deschesnes F, Davis EE, Ruppel J, Su JQ, Adelman DC� Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects� American Journal of Respiratory and Critical Care Medicine 160(3): 1023–1027 (1999)� 39� Catley MC, Coote J, Bari M, Tomlinson KL� Monoclonal antibodies for the treatment of asthma� Pharmacology & Therapeutics 132: 333–351 (2011)� 40� Moss RB, Milla C, Colombo J, Accurso F, Zeitlin PL, Clancy JP et al� Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: A randomized placebo-controlled phase 2b trial� Human Gene Therapy 18: 726–732 (2007)� 41� Zabner J, Ramsey BW, Meeker DP, Aitken ML, Balfour RP, Gibson RL et al� Repeat administration of an adenovirus vector encoding cystic fibrosis transmembrane conductance regulator to the nasal epithelium of patients with cystic fibrosis� Journal of Clinical Investigation 97: 1504–1511 (1996)� 42� Harvey BG, Leopold PL, Hackett NR, Grasso TM, Williams PM, Tucker AL et al� Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus� Journal of Clinical Investigation 104: 1245–1255 (1999)� 43� Moss RB, Rodman D, Spencer LT, Aitken ML, Zeitlin PL, Waltz D et al� Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: A multicenter, doubleblind, placebo-controlled trial� Chest 125: 509–521 (2004)� 44� Griesenbach U, Alton EW� Expert opinion in biological therapy: Update on developments in lung gene transfer� Expert Opinion on Biological Therapy 13: 345–360 (2013)� 22 Advances in Pulmonary Drug Delivery 45� Alton EW, Boyd AC, Cheng SH, Davies JC, Davies LA, Dayan A et al� Toxicology study assessing efficacy and safety of repeated administration of lipid/DNA complexes to mouse lung� Gene Therapy 21(1): 89–95 (2014)� Accessed May, 2014� 46� DNA Science Blog: A Checklist for Gene Therapy from the UK Cystic Fibrosis Trial (2014)� http://blogs�plos�org/dnascience/2014/05/22/checklist-gene-therapy-uk-cysticfibrosis-trial/� Accessed May, 2014� 47� Densmore CL, Orson FM, Xu B, Kinsey BM, Waldrep JC, Hua P et al� Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization� Molecular Therapy 1: 180–188 (2000)� 48� Gautam A, Densmore CL, Xu B, Waldrep JC� Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery� Molecular Therapy 2: 63–70 (2000)� 49� Gautam A, Densmore CL, Waldrep JC� Pulmonary cytokine responses associated with PEI-DNA aerosol gene therapy� Gene Therapy 8: 254–257 (2001)� 50� Gautam A, Densmore CL, Golunski E, Xu B, Waldrep JC� Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes� Molecular Therapy 3: 551–556 (2001)� 51� Densmore CL, Kleinerman ES, Gautam A, Jia S-F, Xu B, Worth LL et al� Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes� Cancer Gene Therapy 8: 619–627 (2001)� 52� Densmore CL� Polyethyleneimine-based gene therapy by inhalation� Expert Opinion on Biological Therapy 3: 1083–1092 (2003)� 53� FDA� Guidance for industry: Gene therapy clinical trials—Observing subjects for delayed adverse events� FDA, Rockville, MD (2006)� 54� Weers JG, Miller DP� Formulation design of dry powders for inhalation� Journal of Pharmaceutical Sciences 104(10): 3259–3288 (2015)� 55� Sakagami M� Systemic delivery of biotherapeutics through the lung: Opportunities and challenges for improved lung absorption� Therapeutic Delivery 4(12): 1511–1525 (2013)� 56� Lechuga-Ballesteros D, Miller DP� Advances in respiratory and nasal drug delivery� Molecular Pharmaceutics 12(8): 2561 (2015)� 57� Muralidharan P, Mallory E, Malapit M, Hayes Jr D, Mansour HM� Inhalable PEGylated phospholipid nanocarriers and PEGylated therapeutics for respiratory delivery as aerosolized colloidal dispersions and dry powder inhalers� Pharmaceutics 6: 333–353 (2014)� 58� DeGeorge J, Ahn CH, Andrews PA, Brower ME, Choi YS, Chun MY et al� Considerations for toxicology studies of respiratory drug products� Regulatory Toxicology and Pharmacology 25: 189–193 (1997)� 59� FDA� Draft guidance for industry and staff: Nonclinical evaluation of reformulated drug products and products intended for administration by an alternate route (2008)� http://www�fda�gov/downloads/drugs/guidancecomplianceregulatoryinform-ation/ guidances/ucm079245�pdf+&cd=1&hl=en&ct=clnk&gl=us� Accessed Jan, 2016� 60� Working PK, Newman MS, Johnson J, Cornacoff JB� Safety of poly(ethylene glycol) and poly(ethylene glycol) derivatives� In Poly(Ethylene Glycol): Chemistry and Biological Applications, Harris M, Zalipsky S, eds� Division of Polymer Chemistry Symposium, 213th National Meeting of the ACS, San Francisco, CA (April 13–17, 1997)� American Chemical Society (ACS), Washington, DC, pp� 45–57 (1998) (ACS Symposium Series, No� 680)� 61� Veronese FM, Mero A� The impact of PEGylation on biological therapies� BioDrugs 22(5): 315–329 (2008)� 62� Gursahani H, Riggs-Sauthier J, Pfeiffer J, Lechuga-Ballesteros D, Fishburn CS� Absorption of polyethylene glycol (PEG) polymers: The effect of PEG size on permeability� Journal of Pharmaceutical Sciences 98(8): 2847–2856 (2009)� 2 More Compelling than Ever Inhaled Insulin John S.

Download PDF sample

Rated 4.56 of 5 – based on 12 votes